Drug Discovery & Molecular Design - software & AI news

Daily news on software, AI, and companies shaping drug discovery & molecular design.

Showing 377 results
minimalist representation of a small molecule

Jun 9, 2026

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Ltd. is set to showcase its advancements in drug discovery at the upcoming BIO International Convention, scheduled for June 22-25, 2026, in San Diego, California.The company, known for its innovative work in computational chemistry and AI-driven design of small molecules, will highlight its recent breakthroughs in pharmaceutical applications. Ofer Haviv, the CEO, along with Dr. Gabi Tarcic and Dr. Olga Nissan, will represent Evogene at the event. Dr. Tarcic is expected to present on the
Flat design of a drug compound and AI agent silhouette

Jun 8, 2026

Owkin, Sanofi Expand AI Collaboration to Develop Drug Discovery Agents

Owkin and Sanofi have deepened their partnership to enhance drug discovery through AI technology, marking a significant step in integrating advanced digital tools into pharmaceutical research.The newly expanded five-year collaboration will leverage Owkin's K Pro AI scientist platform to develop AI-driven agents tailored for Sanofi's drug development processes. This initiative aims to create intelligent assistants capable of executing complex tasks throughout various phases of research and develo
Flat illustration of siRNA molecule and AI model

Jun 6, 2026

How a US$2 Billion Generative AI RNAi Deal At Alnylam Pharmaceuticals (ALNY) Has Changed Its Investment Story

Alnylam Pharmaceuticals has entered a significant partnership with Inceptive Nucleics, valued at up to $2 billion, aimed at leveraging generative AI to enhance RNAi drug discovery. This collaboration includes an initial investment of $30 million and grants Alnylam access to advanced AI models and expertise, notably from Transformer co-inventor Jakob Uszkoreit, to improve siRNA design and overall research productivity.This partnership is poised to reshape Alnylam's investment narrative as it seek
A minimalist representation of a molecule and a computer chip, symbolizing AI in drug discovery.

Jun 6, 2026

NYB.AI Featured in NVIDIA GTC Taiwan

NYB.AI, an AI-driven drug discovery platform, has gained recognition at NVIDIA GTC Taiwan 2026, showcasing its innovative potential in the life sciences sector.Developed by Nanyang Biologics, NYB.AI was highlighted in the opening showcase video at the event, which featured select companies from the NVIDIA Inception ecosystem. This recognition underscores the growing global interest in integrating artificial intelligence with biology and high-performance computing to enhance drug discovery proces
A vial of biopharmaceutical agent on a lab bench

Jun 5, 2026

Sanofi Inks Five-Year Pact to License Owkin’s AI Scientist K Pro for Next-Gen Biopharma Agents

Sanofi has entered a five-year licensing agreement with Owkin to utilize its AI scientist, K Pro, aimed at advancing biopharmaceutical development.This collaboration highlights a growing trend among major pharmaceutical companies to integrate AI technologies into their workflows. Owkin's K Pro is designed to function as an intelligent assistant, streamlining complex tasks in drug research and development. The partnership will enhance Sanofi’s existing capabilities in agentic AI, allowing for mor
A test tube with a colorful liquid on a lab bench

Jun 5, 2026

Earendil: A Blueprint for a Multipolar Life Sciences Era

Earendil Labs' recent $787 million financing marks a pivotal moment in the evolution of life sciences, highlighting a new paradigm in AI-enabled drug discovery.This funding round, one of the largest in the sector, reflects a strategic convergence of geographic and operational strengths from various global players. Earendil, based in Delaware and Beijing, is poised to leverage European scientific expertise, American computational advancements, and China's rapid execution capabilities. This model
A glass vial with clear liquid on a lab bench in a biotechnology lab

Jun 4, 2026

Alnylam, Inceptive ink AI deal potentially worth $2B

Alnylam Pharmaceuticals has announced a significant collaboration with Inceptive Nucleics, aiming to leverage artificial intelligence (AI) for the accelerated discovery of RNA-based therapies. The initial phase of the partnership includes a $30 million investment, with potential total deal value reaching $2 billion contingent on meeting various milestones.This partnership is a key component of Alnylam's broader "Alnylam 2030" strategy, which focuses on expanding its pipeline of innovative therap
Minimalist illustration of a drug compound

Jun 4, 2026

Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive

Alnylam Pharmaceuticals has initiated a significant collaboration with Inceptive, aiming to leverage generative AI to enhance its RNA interference (RNAi) drug discovery efforts. This partnership is strategically aligned with Alnylam's objectives for its Alnylam 2030 pipeline expansion, focusing on accelerating the development of innovative RNAi therapeutics. Inceptive's AI platform is designed to identify complex biological patterns and apply them across various therapeutic contexts without the
A minimalist representation of a molecular structure in a dark color scheme.

Jun 4, 2026

Pfizer to Leverage Chai Discovery’s AI Platform

Pfizer has announced a strategic partnership with Chai Discovery to integrate advanced AI capabilities into its drug development processes.This collaboration will allow Pfizer to utilize Chai's AI platform, specifically the Chai-3 model and a customized version that incorporates Pfizer's proprietary data. The aim is to enhance Pfizer's drug discovery engine, streamlining the identification and development of new therapeutic molecules.Chai Discovery specializes in generative AI technology that ca
A drug compound on a laboratory notebook in a research lab

Jun 4, 2026

Meet Dalton, a new AI-powered drug discovery platform

DaltonTx has launched its AI-driven drug discovery platform, Dalton, aimed at streamlining the entire drug development process.The UK-based start-up DaltonTx has officially introduced its platform, Dalton, which is designed to optimize drug discovery from data analysis to molecular design and decision-making. This innovative platform aims to create a "continuous learning engine" that supports both small-molecule and biologic medicines. With a team comprising former scientists from AstraZeneca, E
A minimalist illustration of a chromosome and genome strand representing advancements in genomics research.

Jun 4, 2026

OpenAI GPT-Rosalind Update Brings Advanced AI Drug Discovery and Genomics Research Capabilities

OpenAI has unveiled a major update to its GPT-Rosalind model, enhancing its capabilities in drug discovery and genomics research.The June 3, 2026 announcement highlights advancements in the GPT-Rosalind series, which is tailored for life sciences research, particularly in drug discovery and genomics. This update integrates the sophisticated features of GPT 5.5, aiming to improve performance in critical areas such as medicinal chemistry and experimental biology. OpenAI emphasizes that progress in
An RNA molecule on a lab bench in a dimly lit laboratory setting.

Jun 4, 2026

AI Collaboration Puts Alnylam’s RNAi Pipeline Productivity In Focus

Alnylam Pharmaceuticals has entered a collaboration with Inceptive Nucleics to enhance RNA interference (RNAi) drug discovery through the application of generative AI models. This partnership aims to streamline the drug design process, potentially increasing the efficiency and speed of developing new therapeutics as part of Alnylam's broader strategy for 2030.The collaboration seeks to leverage Inceptive's expertise in AI to optimize RNAi drug design, thereby shortening the trial-and-error phase